The bispecific EGFR- and MET-directed subcutaneous coformulation produced a 42% objective response rate in the phase 1b/2 OrigAMI-4 trial for patients with pretreated recurrent or metastatic HNSCC.
This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results